There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Pfizer (PFE – Research Report), Progyny (PGNY – Research Report) and IQVIA Holdings (IQV – Research Report) with bullish sentiments.
Pfizer (PFE)
Jefferies analyst Akash Tewari maintained a Buy rating on Pfizer today and set a price target of $39.00. The company’s shares closed last Thursday at $30.47, close to its 52-week low of $28.93.
According to TipRanks.com, Tewari is a 5-star analyst with an average return of
Pfizer has an analyst consensus of Moderate Buy, with a price target consensus of $39.91, which is a 31.7% upside from current levels. In a report issued on November 20, Cantor Fitzgerald also maintained a Buy rating on the stock with a $75.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Progyny (PGNY)
In a report released yesterday, Glen Santangelo from Jefferies reiterated a Buy rating on Progyny, with a price target of $43.00. The company’s shares closed last Thursday at $34.36.
According to TipRanks.com, Santangelo is a 4-star analyst with an average return of
Currently, the analyst consensus on Progyny is a Strong Buy with an average price target of $46.00, a 34.4% upside from current levels. In a report issued on November 20, J.P. Morgan also assigned a Buy rating to the stock with a $49.00 price target.
IQVIA Holdings (IQV)
In a report released yesterday, David Windley from Jefferies maintained a Buy rating on IQVIA Holdings, with a price target of $250.00. The company’s shares closed last Thursday at $214.10.
According to TipRanks.com, Windley is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for IQVIA Holdings with a $235.29 average price target, implying a 10.0% upside from current levels. In a report issued on November 20, Truist Financial also maintained a Buy rating on the stock with a $240.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PFE:
- Arvinas, Pfizer announce updated Vepdegestrant data to be presented at SABCS
- Singapore says Nuvaxovid COVID vaccine won’t be available under NVP as of Jan. 1
- Biden Plans to Boost Drug Production Using Cold-War Era Law
- JPMorgan sees ‘fairly limited downside’ in Pfizer after 2023 selloff
- Moderna tells Reuters will appeal European Patent Office decision
